Mirvetuximab Soravtansine (Elahere)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses mirvetuximab soravtansine (Elahere), 5 mg/mL, concentrate for solution for injection, IV infusion. Indication: As monotherapy indicated for the treatment of adult patients with folate receptor (FR-alpha) alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1 to 3 prior systemic treatment regimens.